PRODUCTS / CANCER PRE-SCREENING
A New Approach to Cancer Detection
One test for
4 CANCER TYPES
50% of cancer cases
Just breathe for
3 MINUTES
That's it
Easy-to-Use
AT-HOME TEST
In 3 simple steps
SpotitEarly is designed to address the most common barriers with a simple test that:
-
Is non-invasive
-
Uses samples collected in the comfort of home
-
Easy prescription, no appointments or lost work days
-
Requires no healthcare professionals for sample collection
-
Has zero side effects
-
Can serve rural or other areas located far from medical facilities
SpotitEarly
Breast Cancer Detection
Product Rollout
Breaking the Barriers to Cancer Pre-Screening
1
Online Prescription
& Ordering
2
Breathe for
3 Minutes
3
Send to Lab
& Get Results
Trial results show high sensitivity to breast cancer, with an overall accuracy rate of 95%
Breast cancer is the most common cause of cancer death among women worldwide, with over 2.3 million cases diagnosed annually.
Accurate detection at early stages can offer patients more treatment options, help maintain better quality of life during therapy, and greatly improve the prognosis to save more lives.
Reliably pre-screening larger segments of the population will return peace of mind to high-risk groups, direct patients to treatment earlier, reduce overdiagnosis and overtreatment, potentially increase survival rates—all this while reducing costs and required care resources.
Having a test with no side effects, makes SpotitEarly a perfect fit for high-risk groups, including BRCA carriers, who need to undergo frequent routine screening tests, as well as for the dense breast tissue population.
Covering 50% of New Cancer Cases
The recently completed Rainbow Study showed how SpotitEarly's pre-screening platform effectively detected 4 common cancer types—Breast, Lung, Colon and Prostate—which make up 50% of new cancer cases globally. We are onboarding each one of these 4 common cancer types, one by one, to create a single test to cover all. As we embark on two new trials—the Pink and the White Studies—we have chosen to focus on the most common (Breast) and the most lethal (Lung) cancer types first.
In its trial covering Breast Cancer, the Rainbow Study of SpotitEarly’s test, was found to have sensitivity of 95% for breast cancer even at early stages of the disease. Aiming to achieve even higher clinical validation, a new trial—the Pink Study—is already underway.
SpotitEarly’s test will be so easy to perform that even people with limited or no access to medical centers could get checked regularly, and rest at ease.
For people at high risk of developing lung cancer. SpotitEarly tests show high accuracy even at early stages of the disease.
The SpotitEarly Lung test could change the lives of these populations, directing them to further testing and eventual diagnosis at a much earlier stage for which many more treatment options exist.
Currently, between 40% to 60% of lung cancer cases are detected at advanced stages when they are no longer localized, which makes 5-year survival rates lower than other common cancer types. Lung cancer is the most common type in men and the 2nd most common in women.
The high accuracy both in terms of sensitivity and specificity of the SpotitEarly test could change mortality statistics worldwide, reduce suffering, improve quality of life, and bring savings in treatment costs.
Trial results show a very high sensitivity to lung cancer, with an accuracy rate of 95%
SpotitEarly
Lung Cancer Detection
In its original trial covering Lung Cancer, the Rainbow Study, SpotitEarly’s test was found to have sensitivity of 95% for lung cancer even at early stages of the disease. To achieve even more solid clinical validation, we have launched a new trial, the White Study.
SpotitEarly’s test would serve people with limited or no access to medical centers, allowing them to get checked regularly, and rest at ease.
Coming Soon
Prostate Cancer Detection
About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. In 2023, it was estimated that approximately 288,300 new cases of prostate cancer would be diagnosed in the United States, and about 34,700 men would die from the disease. SpotitEarly's solution has shown 97% sensitivity in the early stages within the Rainbow observational study.
Colorectal Cancer Detection
Colorectal cancer is the third most commonly diagnosed cancer type in both men and women in the United States. According to the American Cancer Society, it was estimated that there would be about 153,020 new cases of colorectal cancer in 2023, with approximately 52,550 deaths resulting from the disease. SpotitEarly's solution has shown 86% sensitivity in the early stages within the Rainbow observational study.
A Single Test - 4 Cancer Types
Wider Coverage, Higher Efficiency
Overloaded healthcare systems face tough choices when it comes to risk stratification for preventative cancer screening. SpotitEarly pre-screening is designed as an extra measure to provide some relief and reach populations not currently covered.
A New Paradigm in Cancer Detection
Covers
4 CANCER TYPES
50% of cancer cases
It takes
JUST BREATHE
to activate
Easy-to-use
AT-HOME TEST
in 3 simple steps
3
Get
results
2
Breathe
3 minutes
1
Order test KIT
JUST BREATHE
A New Paradigm in Cancer Detection
1
Order test KIT
2
Breathe
3 minutes
3
Get
results
Easy-to-use
AT-HOME TEST
3 simple steps
Covers
4 COMMON TYPES
of cancer
covers
4 COMMON TYPES
of cancer
easy-to-use
AT-HOME TEST
3 simple steps
1
ORDER
TEST KIT
2
BREATHE
3 MINUTES
3
GET
RESULTS
JUST BREATHE
A New Paradigm
in cancer detection
SpotitEarly is at the forefront of a paradigm shift in cancer screening. The company’s innovative product, based on a simple breath sample, revolutionizes the screening process, making it easy to use, non-intimidating, and highly accessible. Our breakthrough technology enables us to deliver results for multiple types of cancer in a single test. By simplifying the screening process and addressing the common barriers to early detection, we aim to significantly increase adherence to cancer screening. Ultimately, this will lead to earlier diagnoses, saving lives, and lowering the overall cost of cancer care.
Len Lichtenfeld, MD MACP
Chief Medical Officer , SpotitEarly
Dense Breast Tissue
SpotitEarly’s test has proven to be accurate in cases of dense breast tissue too, giving new hope to more patients.
High-risk Groups
BRCA Carriers and other high-risk groups undergo frequent routine screening tests, and yet still live with the fear of cancer.
A New Approach to Cancer Detection
One test for
4 CANCER TYPES
50% of cancer cases
Just breathe for
That's it
Easy-to-Use
AT-HOME TEST
In 3 simple steps
4 Major Cancers, 50% of All Cases
